Johnson Johnson's Amivantamab Shows Promise in Eradicating Tumors in Cancer Patients
A recent international trial has demonstrated promising results for a cancer treatment developed by Johnson & Johnson. The treatment, known as amivantamab, was tested on patients whose cancer had spread or returned after failing to respond to other treatments. The trial, which spanned 11 countries, showed that the injection could shrink tumors in more than a third of patients, with dramatic changes observed within weeks. In 15 patients, the drug completely eradicated their tumors. The treatment targets cancer in three ways: blocking the epidermal growth factor receptor (EGFR), inhibiting the MET pathway, and activating the immune system to attack the tumor. The results of the trial will be presented at the American Society of Clinical Oncology's annual meeting in Chicago. 
